Trogenix announces publication of breakthrough pre-clinical data in Nature demonstrating complete tumour eradication and durable protection in aggressive brain cancer model
A single-dose of Trogenix’s proprietary Synthetic Super-Enhancers achieved complete tumour elimination in…
New SPRAVATO (esketamine nasal spray) data support robust effectiveness and show durable effect for treatment resistant depression in a real-world setting
Johnson & Johnson presents findings from the largest European real-world dataset for…
Celldex Presents Positive Data from Phase 2 Chronic Spontaneous Urticaria and Phase 2 Cold Urticaria and Symptomatic Dermographism Studies Demonstrating Rapid, Profound and Durable Improvements in Patient Quality of Life at AAD 2026
March 27, 2026 10:30 ET | Source: Celldex Therapeutics, Inc. - Improvements…
Aerospike NoSQL Database 8 Delivers Durable and Low-Latency Memory Store for LangGraph Agentic AI Workflows
MOUNTAIN VIEW, Calif., March 25, 2026 (GLOBE NEWSWIRE) -- Aerospike Inc. today…
Lyell Immunopharma Presents New Clinical Data from Ongoing Trial of Ronde-Cel Showing High Rates of Durable Complete Responses in Patients with Large B-cell Lymphoma at the 67th ASH Annual Meeting and Exposition
93% overall response and 76% complete response rates with median progression-free survival…
Des pas en alimentation durable mais trop petits pour bien nourrir tout le Qubec
Dévoilement de la politique bioalimentaire 2025-2035 August 22, 2025 12:52 ET |…
Crinetics to Present New Long-Term Data Demonstrating Durable Control of Once-Daily, Oral PALSONIFY (Paltusotine) in Acromegaly at ENDO 2025
July 13, 2025 17:45 ET | Source: Crinetics Pharmaceuticals, Inc. Data show…
Neurona Announces Publication in Neuron Reporting Durable Preclinical Engraftment of Human Interneuron Cell Therapy
SAN FRANCISCO, July 11, 2025 (GLOBE NEWSWIRE) -- Neurona Therapeutics, a clinical-stage…
Investigational combination of first-in-class bispecific antibodies TALVEY (talquetamab) and TECVAYLI (teclistamab) shows deep and durable responses in heavily pretreated multiple myeloma patients with extramedullary disease
Results from the Phase 2 RedirecTT-1 study demonstrate deep responses with 78.9…
